Tag: $Biogen

Biogen reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected.

TOKYO, Sept 25 (Reuters) – Japan’s Eisai  said on Monday the country’s health ministry had approved its Alzheimer treatment Leqembi, co-developed with U.S.-based Biogen.

Biogen  said Friday it will acquire Reata Pharmaceuticals   in a deal valued at $7.3 billion.

The FDA decision marks a new milestone for a fatal disease that has eluded drugmakers’ efforts for decades. Trial data showed that the treatment slows progression of the brain-wasting disease by 27% for patients in the earliest stages of Alzheimer’s.

Alzheimer’s disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.

Biogen and Eisai are headed back to face the Food and Drug Administration’s outside neurology experts, two and a half years after the same panel dealt what proved to be a decisive blow to their Alzheimer’s disease therapy, Aduhelm.